Photo: press service of the RF Ministry of Defense / RIA Novosti
Post-registration clinical trials of a coronavirus vaccine are starting in Moscow, 40 thousand people will take part in the study. This is stated in the message of the Russian Direct Investment Fund (RDIF), received by RBC.
Russian Direct Investment Fund, Sovereign Fund of the Russian Federation, Moscow Government and National Research Center for Epidemiology and Microbiology named after N.F. The Gamaleis announce the start of a post-registration clinical trial, ”the message says.
Gamaleya Center eliminated the need to take tests before vaccination
With the support of RDIF, tests will be carried out in five more countries.
Russians over 18 years old with a Moscow compulsory medical insurance policy can participate in the study. In addition, candidates should not be sick with SARS, not have contact with those infected with coronavirus at least two weeks before the start of vaccination, and also not be sick with COVID-19.